Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations
Tóm tắt
Từ khóa
Tài liệu tham khảo
Allard J Le Guillou D Begriche K Fromenty B (2019) Chapter three - drug-induced liver injury in obesity and nonalcoholic fatty liver disease, in Advances in Pharmacology ( Ramachandran A Jaeschke H , eds) pp 75–107, Elsevier.
Arab, 2018, The evolving role of liver biopsy in non-alcoholic fatty liver disease, Ann Hepatol, 17, 899, 10.5604/01.3001.0012.7188
Brenner D Hall E (2007) Computed tomography — an increasing source of radiation exposure. http://dx.doi.org.proxy.insermbiblio.inist.fr/101056/NEJMra072149 , doi: 10.1056/NEJMra072149, Massachusetts Medical Society.
Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006
Chen, 2018, Combatting fibrosis: exosome‐based therapies in the regression of liver fibrosis, Hepatol Commun, 3, 180, 10.1002/hep4.1290
Deffieux, 2015, Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography, J Hepatol, 62, 317, 10.1016/j.jhep.2014.09.020
Dioguardi Burgio, 2019, Ultrasonic adaptive sound speed estimation for the diagnosis and quantification of hepatic steatosis: a pilot study, Ultraschall Med -. Ultraschall Med, 40, 722, 10.1055/a-0660-9465
Doycheva, 2016, Non-invasive screening for NAFLD and advanced fibrosis in diabetes in primary care setting by MRI and MRE, Aliment Pharmacol Ther, 43, 83, 10.1111/apt.13405
Dulai, 2016, MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice, J Hepatol, 65, 1006, 10.1016/j.jhep.2016.06.005
Fedchuk, 2014, Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1209, 10.1111/apt.12963
Goldberg, 2017, Changes in the prevalence of hepatitis C virus infection, non-alcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152, 1090, 10.1053/j.gastro.2017.01.003
Imbault, 2018, Ultrasonic fat fraction quantification using in vivo adaptive sound speed estimation, Phys Med Biol, 63, 215013, 10.1088/1361-6560/aae661
Imbault, 2017, Robust sound speed estimation for ultrasound-based hepatic steatosis assessment, Phys Med Biol, 62, 3582, 10.1088/1361-6560/aa6226
Lammert, 2019, Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury, Clin Gastroenterol Hepatol, 17, 2814, 10.1016/j.cgh.2018.12.013
Li, 2018, Asking the right questions with animal models: methionine- and choline-deficient model in predicting adverse drug reactions in human NASH, Toxicol Sci, 161, 23, 10.1093/toxsci/kfx253
Li, 2018, Current status of imaging in nonalcoholic fatty liver disease, World J Hepatol, 10, 530, 10.4254/wjh.v10.i8.530
Madrazo, 2017, Diagnosis of nonalcoholic steatohepatitis without liver biopsy, Gastroenterol Hepatol (N Y), 13, 378
Malhi, 2019, Emerging role of extracellular vesicles in liver diseases, Am J Physiol Gastrointest Liver Physiol, 317, G739, 10.1152/ajpgi.00183.2019
Massart, 2017, Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity, J Clin Transl Res, 3, 212
Newman, 2020, Role of extracellular vesicles in the pathophysiology, diagnosis and tracking of non-alcoholic fatty liver disease, J Clin Med, 9, 2032, 10.3390/jcm9072032
Obika, 2012, Diagnosis and evaluation of nonalcoholic fatty liver disease, Exp Diabetes Res, 2012, 145754, 10.1155/2012/145754
Okushin, 2016, The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease, J Gastroenterol, 51, 808, 10.1007/s00535-015-1148-y
Poynard, 2019, The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis, Eur J Gastroenterol Hepatol, 31, 393, 10.1097/MEG.0000000000001304
Pu, 2019, Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis, BMC Gastroenterol, 19, 51, 10.1186/s12876-019-0961-9
Ruffillo, 2011, Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease, J Hepatol, 54, 160, 10.1016/j.jhep.2010.06.028
Vildhede, 2020, Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease, Clin Pharmacol Ther, 107, 1128, 10.1002/cpt.1699
Younossi, 2018, The epidemiology of nonalcoholic steatohepatitis, Clin Liver Dis (Hoboken), 11, 92, 10.1002/cld.710
Younossi, 2018, Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis, Hepatology, 68, 349, 10.1002/hep.29721
Younossi, 2021, Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 19, 580, 10.1016/j.cgh.2020.05.064
Zhou, 2019, Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice, World J Gastroenterol, 25, 1307, 10.3748/wjg.v25.i11.1307